JP2023543801A - レトロインベルソ制御性ｔ細胞エピトープ - Google Patents

レトロインベルソ制御性ｔ細胞エピトープ Download PDF

Info

Publication number
JP2023543801A
JP2023543801A JP2023519066A JP2023519066A JP2023543801A JP 2023543801 A JP2023543801 A JP 2023543801A JP 2023519066 A JP2023519066 A JP 2023519066A JP 2023519066 A JP2023519066 A JP 2023519066A JP 2023543801 A JP2023543801 A JP 2023543801A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
amino acids
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543801A5 (https=
Inventor
ディ グルート アン
マーティン ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epivax Inc
Original Assignee
Epivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epivax Inc filed Critical Epivax Inc
Publication of JP2023543801A publication Critical patent/JP2023543801A/ja
Publication of JP2023543801A5 publication Critical patent/JP2023543801A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023519066A 2020-09-25 2021-09-24 レトロインベルソ制御性ｔ細胞エピトープ Pending JP2023543801A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063083392P 2020-09-25 2020-09-25
US63/083,392 2020-09-25
PCT/US2021/052017 WO2022067076A1 (en) 2020-09-25 2021-09-24 Retro-inverso regulatory t cell epitopes

Publications (2)

Publication Number Publication Date
JP2023543801A true JP2023543801A (ja) 2023-10-18
JP2023543801A5 JP2023543801A5 (https=) 2024-10-02

Family

ID=80845816

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519066A Pending JP2023543801A (ja) 2020-09-25 2021-09-24 レトロインベルソ制御性ｔ細胞エピトープ

Country Status (8)

Country Link
US (1) US20240173377A1 (https=)
EP (1) EP4216984A4 (https=)
JP (1) JP2023543801A (https=)
KR (1) KR20230074517A (https=)
AU (1) AU2021350011A1 (https=)
CA (1) CA3193819A1 (https=)
MX (1) MX2023003426A (https=)
WO (1) WO2022067076A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010516290A (ja) * 2007-01-30 2010-05-20 エピバックス インコーポレーテッド 調節性ｔ細胞エピトープ、組成物およびその使用
JP2019525897A (ja) * 2016-06-10 2019-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 リジン結合体化免疫グロブリン
JP2021503276A (ja) * 2017-10-05 2021-02-12 エピバックス、インコーポレイテッド 制御性ｔ細胞エピトープ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
WO2012142022A1 (en) * 2011-04-11 2012-10-18 The General Hospital Corporation Assays, compositions, systems, kits, and devices for diagnosing typhoid fever

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010516290A (ja) * 2007-01-30 2010-05-20 エピバックス インコーポレーテッド 調節性ｔ細胞エピトープ、組成物およびその使用
JP2019525897A (ja) * 2016-06-10 2019-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 リジン結合体化免疫グロブリン
JP2021503276A (ja) * 2017-10-05 2021-02-12 エピバックス、インコーポレイテッド 制御性ｔ細胞エピトープ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CURRENT OPINION IN BIOTECHNOLOGY, vol. 9, JPN7025003834, 1998, pages 377 - 382, ISSN: 0005787583 *

Also Published As

Publication number Publication date
KR20230074517A (ko) 2023-05-30
US20240173377A1 (en) 2024-05-30
AU2021350011A9 (en) 2025-03-13
EP4216984A4 (en) 2025-03-05
MX2023003426A (es) 2023-04-27
CA3193819A1 (en) 2022-03-31
EP4216984A1 (en) 2023-08-02
WO2022067076A1 (en) 2022-03-31
AU2021350011A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
US20230242591A1 (en) Regulatory t cell epitopes and detolerized sars-cov-2 antigens
JP2021107444A (ja) 調節性ｔ細胞エピトープ、組成物およびその使用
US12583891B2 (en) Peptides and methods for the treatment of diabetes
JP7274472B2 (ja) 制御性ｔ細胞エピトープ
US20240316101A1 (en) Regulatory t cell epitopes
JP2023543801A (ja) レトロインベルソ制御性ｔ細胞エピトープ
US20230279072A1 (en) Regulatory t cell epitopes
US20230321237A1 (en) Regulatory t cell epitopes
US20230158165A1 (en) Tregitope constructs useful in the prevention and treatment of type 1 diabetes
JP2023538002A5 (https=)
JP2023520989A5 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240924

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260427